P-048 Prevalence of Gluten Free Diet and Symptom Improvement in Patients with Inflammatory Bowel Diseases in CCFA Partners Cohort

• DOI: 10.1097/01.mib.0000438995.91953.7c
• Publication Date: 2013-11-18T20:11:11Z
• Authors: Hans Herfarth; Christopher Martin; Robert Sandler; Michael Kappelman; Wenli Chen; Elizabeth Jaeger; Millie Long
• Keywords: Bloating; Gluten free

Dietary interventions have been viewed as a possible therapeutic modality in adult inflammatory bowel diseases (IBD) patients, but so far clinical trials investigating diets failed to yield significant benefit. Adherence gluten free diet (GFD) without an underlying diagnosis of celiac disease has enjoyed rapid and widespread adoption the US recent years currently at least 0.5% population follow GFD. A new entity designated non-celiac sensitivity associated with GI-symptoms such bloating, diarrhea, abdominal pain, fatigue nausea. Many these symptoms can also be found IBD patients. We therefore analyzed prevalence effects GFD patients IBD. characteristics responses cross-sectional questionnaire in1647 participating CCFA Partners, longitudinal, internet-based cohort. Questions included whether individual carried or sensitivity, past current practice improvement specific GI- flares while on For users we degree adherence using validated questionnaire. Bivariate statistics were used compare rates by symptom adherence. Ten (0.6%) 81 (4.9%) had diagnosed respectively. Three hundred fourteen (19.1%) participants reported ever having tried 135 (8.2%) adhering it. No differences between non-GFD groups regard type, duration disease, educational status (Table 1). Fewer individuals who attempted 5-ASA (5-aminosalicylic acid) medications. higher percentage people not responding biologics 2). Overall 206/314 (65.6%) all trying any GI-symptom. total 38.3% thought they experienced fewer less severe 23.6% requiring medications control being Improvements nausea 56.5%, 42.6%, 41.5%, 27.5% GFD, was excellent 56/135 (41.5%), average 46/135 (34.1%), fair/poor 33/135 (24.4%). Fatigue significantly improved (P < 0.03), whereas no for other symptoms. substantial number this cohort The is comparable general population. More than half report improvement, suggesting that could suffer from sensitivity. responders biologic medications, demonstrating flare those more may respond Future studies should evaluate if are exposure and/or mechanism dietary approach.